You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

June 28, 2018

Vietnam Prime Minister Issues Directive on Combatting Pharmaceutical and Cosmetics Fakes

On June 19, 2018, Vietnam’s prime minister issued Directive No. 17/CT-TTg on strengthening the fight against smuggling, commercial fraud, and the production and trade of fake goods and low-quality goods for pharmaceuticals, cosmetics, and functional foods (Directive 17). Directive 17 states that, while tens of thousands of cases have been discovered and handled, the situation still needs improvement, as infringers are using more complex methods and are located not only in urban areas, but also in many remote regions.

The prime minister implores the relevant ministries and authorities to redouble their efforts and be more aware and proactive. It is noted that, in the age of the Internet, products are broadly advertised online, and although consumers can access a wealth of information on health products, that information is often inaccurate. This leads to an urgent situation where products can have dangerous effects on health and the market.

To rectify the situation, the prime minister assigned the relevant authorities to undertake several urgent tasks. For example, the Ministry of Health was tasked to:

  • Update relevant legal documents on technical standards and the inspection of pharmaceutical and cosmetics products;
  • Increase the application of technology to control the origin and quality of raw materials; privatize testing services; share information on licensing of products; and cooperate with other relevant authorities to fight against smuggled, low quality, and fake goods; and
  • Increase investigations into activities in the licensing, circulation, advertising, testing, and certification of drugs and cosmetics, and increase ad hoc inspections.

The Ministry of Science and Technology was also tasked to strengthen the handling of IP violations in pharmaceuticals and cosmetics. The Market Surveillance Department (MSD) was specifically requested to conduct a general inspection all over the country into manufacturers of pharmaceuticals, cosmetics, and functional foods and strictly handle violations, including IP infringements. This is a new development as the MSD was previously only entitled to inspect traders and products on the market level, rather than manufacturers. Other tasks were assigned to the Ministry of Public Security, Ministry of Defense, Ministry of Industry and Trade, Ministry of Finance, Ministry of Information and Communications, Ministry of Justice, and Steering Committee No. 389 (in charge of the fight against smuggling and anti-counterfeiting).

RELATED INSIGHTS​ 

May 17, 2021
The latest updates to Practical Law’s Life Sciences Global Guide feature contributions from Tilleke & Gibbins attorneys in the firm’s Phnom Penh office, who wrote “Medicinal Product Regulation and Product Liability in Cambodia.” This overview form Practical Law covers a range of regulatory issues related to the marketing and selling of pharmaceutical products, including the following: Regulatory overview, including relevant authorities, scope, definitions, and general procedures for pharmaceuticals, biologicals, and medical devices and health care IT Pricing, government funding, and reimbursement: Structure of the Cambodian health care system, price regulation, and reimbursement Clinical trials Manufacturing and distribution Marketing: Authorization for marketing medicinal products, parallel imports and cross-border trade in medicines Restrictions on dealings with health care professionals Selling restrictions Advertising and promotion Data privacy Packaging, labeling, and tracking Product safety, quality, and liability Local establishment, representation, and residency requirements Reform The full Medicinal Product Regulation and Product Liability in Cambodia chapter can be accessed on the Practical Law website. Practical Law, produced by Thomson Reuters, is the world’s leading legal know-how resource for business lawyers, publishing a huge range of guides covering hundreds of jurisdictions and practice areas.
April 19, 2021
Thailand has made significant changes to its statutory interest rate framework for the first time in almost a century. Since 1925, the statutory interest rate codified in Thailand’s Civil and Commercial Code (the CCC) has remained at 7.5% per year. But with Covid-19 having an unprecedented impact on the Thai economy, the Thai Government, via emergency decree, has reduced the statutory rate. While the decree is largely aimed at providing relief to hard-hit SMEs and individual debtors, the amendments have broader implications for doing business in Thailand. Main Changes The new interest rate revisions are contained within the Emergency Decree Amending the Civil and Commercial Code B.E. 2564 (2021) (the Emergency Decree), which was published in the Government Gazette on April 10, 2021 and came into effect on April 11, 2021. The Emergency Decree amends Sections 7 and 224 of the CCC, which stated the previous statutory interest rate of 7.5% per year. The Emergency Decree makes three major changes. The first involves a reduction of the statutory interest rate from 7.5% per year to 3% per year in Section 7. The new 3% annual rate is subject to review every three years by the Ministry of Finance. The interest rate is subject to further change later by a royal decree. The second change concerns money debts under Section 224 of the CCC. The previous version of Section 224 stated, among other things, that a money debt based on a default bears interest of 7.5% per year. Under the Emergency Decree, the new actual statutory default interest rate is the statutory interest rate stated in Section 7 with an additional rate of 2% per year. The result is a 5% annual statutory default interest rate. Since the statutory default interest rate is based in part on the Section 7